12/5
08:30 am
iccm
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
Neutral
Report
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
11/26
08:10 pm
iccm
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
Medium
Report
Icecure Medical Ltd (ICCM) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... [Yahoo! Finance]
11/19
07:04 pm
iccm
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 [Yahoo! Finance]
Medium
Report
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 [Yahoo! Finance]
11/19
12:59 pm
iccm
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/19
08:54 am
iccm
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
Low
Report
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
11/18
07:06 pm
iccm
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer [Yahoo! Finance]
Medium
Report
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer [Yahoo! Finance]
11/18
08:30 am
iccm
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
Medium
Report
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
11/14
04:30 pm
iccm
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
Low
Report
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
11/12
08:30 am
iccm
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
Medium
Report
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
11/10
08:41 am
iccm
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction [Yahoo! Finance]
Medium
Report
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction [Yahoo! Finance]
11/10
08:30 am
iccm
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
Low
Report
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
11/3
08:30 am
iccm
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
High
Report
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
10/13
08:51 am
iccm
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances [Yahoo! Finance]
Low
Report
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances [Yahoo! Finance]
10/13
08:30 am
iccm
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
Medium
Report
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
10/9
08:30 am
iccm
IceCure Medical to Attend the 2025 Maxim Growth Summit
Low
Report
IceCure Medical to Attend the 2025 Maxim Growth Summit
10/8
12:25 pm
iccm
IceCure Medical (NASDAQ:ICCM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
IceCure Medical (NASDAQ:ICCM) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/7
08:10 am
iccm
IceCure Medical (NASDAQ:ICCM) had its price target raised by analysts at HC Wainwright from $2.00 to $2.50. They now have a "buy" rating on the stock.
Low
Report
IceCure Medical (NASDAQ:ICCM) had its price target raised by analysts at HC Wainwright from $2.00 to $2.50. They now have a "buy" rating on the stock.
10/6
11:53 am
iccm
IceCure Medical Ltd (ICCM) U.S. Food And Drug Administration's Marketing Authorization For ProSense Cryoablation Call Transcript [Seeking Alpha]
Low
Report
IceCure Medical Ltd (ICCM) U.S. Food And Drug Administration's Marketing Authorization For ProSense Cryoablation Call Transcript [Seeking Alpha]
10/6
11:27 am
iccm
IceCure Medical Ltd - Special Call [Seeking Alpha]
Low
Report
IceCure Medical Ltd - Special Call [Seeking Alpha]
10/3
12:45 pm
iccm
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above [Yahoo! Finance]
Low
Report
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above [Yahoo! Finance]
10/3
12:45 pm
iccm
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care [Yahoo! Finance]
Low
Report
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care [Yahoo! Finance]
10/3
12:28 pm
iccm
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
Low
Report
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
10/3
12:19 pm
iccm
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
Low
Report
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
9/30
08:30 am
iccm
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
Low
Report
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
9/22
08:49 am
iccm
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented [Yahoo! Finance]
Low
Report
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented [Yahoo! Finance]